Chief Executive Officer
Mark joined Quotient as Chief Executive Officer in 2005 and has over 25 years’ experience in the pharmaceutical and biotech industry. He has worked in a range of organizations including large multinational pharmaceutical companies through to private venture funded biotechnology companies. Following his PhD (Biochemistry, University of Edinburgh) and post-doctoral research (Biochemistry, Biozentrum, Basel), Mark began his pharmaceutical R&D career at Novartis (then Sandoz) in Switzerland and then AstraZeneca in the U.K. During this time he was responsible for discovery projects across a number of therapeutic areas. Mark then joined Incyte Pharmaceuticals, a Californian biotechnology company, where he was responsible for a business unit focused on the application of genomic technologies to pre-clinical development. He returned to the U.K. with Incyte Pharmaceuticals to head up European Business Operations and was responsible for leading that organisation to record levels of performance. Prior to joining Quotient, Mark was the Chief Business Officer at Oxagen, a U.K. biotech company focused on novel therapeutics for Respiratory diseases.
Gordon Cameron OBE
Chief Financial Officer
Gordon joined Quotient in 2007 as CFO and is responsible for all financial matters, including financial reporting, liaising with Quotient’s investors and lenders and leading fund-raisings and M&A activities. Gordon has over 25 years’ experience in the pharmaceutical and biotech industry, in both private equity-backed and public companies. He spent 11 years as CFO and then CEO of Acambis plc, a FTSE-350 vaccines development company. He headed up Acambis’ U.S. operations for five years, delivering a $500 smallpox vaccine counter-bioterrorism contract for the U.S. Government. Prior to that Gordon spent six years as an investment banker, primarily with N M Rothschild, where he advised clients on a variety of corporate finance transactions. He qualified as a Chartered Accountant with Ernst & Young. In 2004, Gordon was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry in the U.S.
Mr. Glassell has more than 25 years of experience in the pharmaceutical industry with a focus on the production of biologic and chemical active pharmaceutical ingredients, drug product manufacturing and medical devices. Mr. Glassell has been a director of the board at Cambrex since 2016 and currently serves as non-executive chairman of the board of LSNE Contract Manufacturing. From 2011 to 2015, he was CEO of CMC Biologics, a contract manufacturing organization focused on biologic pharmaceuticals. Previously, he held senior positions and served on the boards of several public and private life sciences companies, including Vitrolife AB, Cellartis AB, Nobel Chemicals, Berol Nobel, Cerus, CMC Biologics, Swedish American Chamber of Commerce, and the Swedish Chemical Industry Association.
Mubasher Sheikh is a Partner and Head of the Healthcare team at Permira. Since joining the firm in 2012, he has worked on a number of transactions including Althea, Corin, I-MED, LSNE and Quotient Sciences. Prior to joining Permira, Mubasher worked for McKinsey & Company, where he held multiple leadership positions in the Pharmaceutical and Medical Products Group. Prior to that he spent five years as a transplant physician at Academic Medical Centres in London and Cambridge. Mubasher holds both a degree and post-graduate degree in Medicine from the University of London, England, and the Royal College of Physicians, England.
Gregory Petros focuses on investment opportunities in the Healthcare sector at Permira. Since joining in 2014 he has worked on a number of transactions including JMO, Schustermann & Borenstein and Quotient Sciences as well as being part of the monitoring team for Corin. Prior to joining Permira, Gregory worked at Boston Consulting Group and he holds a degree in Medicine from the University of Oxford.